Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | SBH Diagnostics signs exclusive license to offer the CPEP3 Assay in their CLIA-certified lab(Natick, MA) April 2, 2013. SBH Diagnostics, Inc. announced the signing of an exclusive licensing agreement with Mercodia AB, allowing them to offer the highly anticipated CPEP3 in the US and Canada for diagnostic testing.
By: SBH Diagnostics Various groups, including the AACC (American Association for Clinical Chemistry) and Dr. Denise Faustman, Massachusetts General, Boston MA, have highlighted the value of this assay in several peer-reviewed publications. The CPEP3 assay not only has important potential implications for patients and clinicians, it also allows for changes in inclusion criteria and monitoring during trials that assess treatments targeting those with long-term Type 1 diabetes. This can lead to interventional therapies to mitigate the life-threatening complications of diabetes. SBH Diagnostics will include the CPEP3 in their CLIA Lab test portfolio, making it available to clinicians in addition to those conducting clinical trials and companies involved with diabetes diagnosis, management, therapeutics and devices. SBH Diagnostics (www.sbhdiagnostics.com) Mercodia AB (www.mercodia.com) For further information, please contact: Marvin A. Collin, Vice President Business Development SBH Diagnostics 617-680-9792 macollin@sbhdiagnostics.com General information about SBH Diagnostics may be found at: http://www.sbhdiagnostics.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|